Pharmaceuticals: Beating the Hell Out of the Average

Jonathan Nitzan and Shimshon Bichler

EconStor Preprints from ZBW - Leibniz Information Centre for Economics

Abstract: A lot has been written on the imminent decline of pharmaceuticals: their falling production, reduced R&D, declining innovation, the opioid crisis, patent cliffs, biting competition from generic drugs, growing opposition to IPR. The list goes on. Judging by the yardsticks that matter the most, though – namely, the companies’ relative profit and relative capitalization – pharmaceuticals are doing just fine. In fact, based on these yardsticks, they remain the most powerful corporate sector of all.

Keywords: capitalization; finance; pharmaceutical; power; profit (search for similar items in EconPapers)
JEL-codes: P16 P26 (search for similar items in EconPapers)
Date: 2021
New Economics Papers: this item is included in nep-ino
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.econstor.eu/bitstream/10419/234557/1/2 ... f_the_average_rn.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:zbw:esprep:234557

Access Statistics for this paper

More papers in EconStor Preprints from ZBW - Leibniz Information Centre for Economics Contact information at EDIRC.
Bibliographic data for series maintained by ZBW - Leibniz Information Centre for Economics ().